Top

Published in:

Open Access 01-12-2013 | Review

Admission prevention in COPD: non-pharmacological management

Authors: Eui-Sik Suh, Swapna Mandal, Nicholas Hart

Published in: BMC Medicine | Issue 1/2013

Abstract

Exacerbations of chronic obstructive pulmonary disease (COPD) are one of the commonest causes of hospital admission in Europe, Australasia, and North America. These adverse events have a large effect on the health status of the patients and impose a heavy burden on healthcare systems. While we acknowledge the contribution of pharmacotherapies to exacerbation prevention, our interpretation of the data is that exacerbations continue to be a major burden to individuals and healthcare systems, therefore, there remains great scope for other therapies to influence exacerbation frequency and preservation of quality of life. In this review, the benefits and limitations of pulmonary rehabilitation, non-invasive ventilation, smoking cessation, and long-term oxygen therapy are discussed. In addition, supported discharge, advanced care coordination, and telehealth programs to improve clinical outcome are reviewed as future directions for the management of COPD.

Please see related article: http://www.biomedcentral.com/1741-7015/11/181.

White P: Prevalence of COPD in primary care: no room for complacency. Fam Pract. 2009, 26: 1-2.PubMed

Akinbami LJ, Liu X: Chronic obstructive pulmonary disease among adults aged 18 and over in the United States, 1998–2009. NCHS Data Brief. 2011, 63: 1-8.PubMed

Zhong N, Wang C, Yao W, Chen P, Kang J, Huang S, Chen B, Wang C, Ni D, Zhou Y, et al: Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med. 2007, 176: 753-760. 10.1164/rccm.200612-1749OC.PubMed

Lin H-H, Murray M, Cohen T, Colijn C, Ezzati M: Effects of smoking and solid-fuel use on COPD, lung cancer, and tuberculosis in China: a time-based, multiple risk factor, modelling study. The Lancet. 2008, 372: 1473-1483. 10.1016/S0140-6736(08)61345-8.

Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC: Chronic obstructive pulmonary disease surveillance–United States, 1971–2000. MMWR Surveill Summ. 2002, 51: 1-16.

National Heart, Lung and Blood Institute. Morbidity and Mortality: 2009 Chartbook of Cardiovascular, Lung and Blood Diseases. 2009, Bethesda (MD): National Institutes of Health

National Collaborating Centre for Chronic Conditions: Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax. 2004, 59: 1-232.

Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, Fabbri LM, Goldin JG, Jones PW, Macnee W, et al: Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010, 182: 598-604. 10.1164/rccm.200912-1843CC.PubMed

Wedzicha JA, Brill SE, Allinson JP, Donaldson GC: Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med. 2013, 11: 181-10.1186/1741-7015-11-181.PubMedPubMedCentral

10.

Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PM, Celli BR, et al: Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008, 31: 416-469. 10.1183/09031936.00099306.PubMed

11.

Donaldson GC, Seemungal TA, Patel IS, Bhowmik A, Wilkinson TM, Hurst JR, Maccallum PK, Wedzicha JA: Airway and systemic inflammation and decline in lung function in patients with COPD. Chest. 2005, 128: 1995-2004. 10.1378/chest.128.4.1995.PubMed

12.

Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA: Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002, 57: 847-852. 10.1136/thorax.57.10.847.PubMedPubMedCentral

13.

Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PMA: Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease. Am J Res Crit Care Med. 2008, 178: 332-338. 10.1164/rccm.200712-1869OC.

14.

Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, Calverley PMA, Celli B, Coxson HO, Crim C, et al: Changes in forced expiratory volume in 1 second over time in COPD. N Eng J Med. 2011, 365: 1184-1192. 10.1056/NEJMoa1105482.

15.

Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA: Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998, 157: 1418-1422. 10.1164/ajrccm.157.5.9709032.PubMed

16.

Halpin DM, Decramer M, Celli B, Kesten S, Liu D, Tashkin DP: Exacerbation frequency and course of COPD. Int J Chron Obstruct Pulmon Dis. 2012, 7: 653-661.PubMedPubMedCentral

17.

Esteban C, Quintana JM, Moraza J, Aburto M, Egurrola M, España PP, Pérez-Izquierdo J, Aguirre U, Aizpiri S, Capelastegui A: Impact of hospitalisations for exacerbations of COPD on health-related quality of life. Respir Med. 2009, 103: 1201-1208. 10.1016/j.rmed.2009.02.002.PubMed

18.

Cote CG, Dordelly LJ, Celli BR: Impact of COPD exacerbations on patient-centered outcomes. Chest. 2007, 131: 696-704. 10.1378/chest.06-1610.PubMed

19.

Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R: Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005, 60: 925-931. 10.1136/thx.2005.040527.PubMedPubMedCentral

20.

Almagro P, Calbo E, Ochoa De Echaguen A, Barreiro B, Quintana S, Heredia JL, Garau U: Mortality after hospitalization for COPD. Chest. 2002, 121: 1441-1448. 10.1378/chest.121.5.1441.PubMed

21.

Groenewegen KH, Schols AM, Wouters EF: Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest. 2003, 124: 459-467. 10.1378/chest.124.2.459.PubMed

22.

Steer J, Norman EM, Afolabi OA, Gibson GJ, Bourke SC: Dyspnoea severity and pneumonia as predictors of in-hospital mortality and early readmission in acute exacerbations of COPD. Thorax. 2012, 67: 117-121. 10.1136/thoraxjnl-2011-200332.PubMed

23.

Connors A, Dawson N, Thomas C, Harrell F, Desbiens N, Fulkerson W, Kussin P, Bellamy P, Goldman L, Knaus W: Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (study to understand prognoses and preferences for outcomes and risks of treatments). Am J Respir Crit Care Med. 1996, 154: 959-967. 10.1164/ajrccm.154.4.8887592.PubMed

24.

Singanayagam A, Schembri S, Chalmers JD: Predictors of mortality in hospitalized adults with acute exacerbation of chronic obstructive pulmonary disease. Ann Am Thoracic Soc. 2013, 10: 81-89.

25.

O’Donnell DE, Parker CM: COPD exacerbations. 3: pathophysiology. Thorax. 2006, 61: 354-361. 10.1136/thx.2005.041830.PubMedPubMedCentral

26.

Gershon AS, Guan J, Victor JC, Goldstein R, To T: Quantifying health services use for chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013, 187: 596-601. 10.1164/rccm.201211-2044OC.PubMed

27.

Royal College of Physicians, British Thoracic Society, British Lung Foundation: Report of the national chronic obstructive pulmonary disease audit 2008: clinical audit of COPD exacerbations admitted to acute NHS trusts across the UK. 2008, Royal College of Physicians

28.

Anstey K, Lowe D, Roberts CM, Hosker H: Report of the 2003 National COPD Audit. 2004, London: Royal College of Physicians/British Thoracic Society

29.

Westert GP, Lagoe RJ, Keskimäki I, Leyland A, Murphy M: An international study of hospital readmissions and related utilization in Europe and the USA. Health Policy. 2002, 61: 269-278. 10.1016/S0168-8510(01)00236-6.PubMed

30.

Reineck LA, Kahn JM: Quality measurement in the affordable care Act. A reaffirmed commitment to value in health care. Am J Res Crit Care Med. 2013, 187: 1038-1039. 10.1164/rccm.201302-0404ED.

31.

Nici L, ZuWallack R, Wouters E, Donner CF: On pulmonary rehabilitation and the flight of the bumblebee: the ATS/ERS statement on pulmonary rehabilitation. Eur Respir J. 2006, 28: 461-462. 10.1183/09031936.06.00075106.PubMed

32.

Barnes PJ, Celli BR: Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009, 33: 1165-1185. 10.1183/09031936.00128008.PubMed

33.

Maltais F, Simard AA, Simard C, Jobin J, Desgagnes P, LeBlanc P: Oxidative capacity of the skeletal muscle and lactic acid kinetics during exercise in normal subjects and in patients with COPD. Am J Respir Crit Care Med. 1996, 153: 288-293. 10.1164/ajrccm.153.1.8542131.PubMed

34.

Porszasz J, Emtner M, Goto S, Somfay A, Whipp BJ, Casaburi R: Exercise training decreases ventilatory requirements and exercise-induced hyperinflation at submaximal intensities in patients with COPD. Chest. 2005, 128: 2025-2034. 10.1378/chest.128.4.2025.PubMed

35.

Hawkins P, Johnson LC, Nikoletou D, Hamnegard CH, Sherwood R, Polkey MI, Moxham J: Proportional assist ventilation as an aid to exercise training in severe chronic obstructive pulmonary disease. Thorax. 2002, 57: 853-859. 10.1136/thorax.57.10.853.PubMedPubMedCentral

36.

Gayan-Ramirez G, Decramer M: Mechanisms of striated muscle dysfunction during acute exacerbations of COPD. J App Physiol. 2013, 114: 1291-1299. 10.1152/japplphysiol.00847.2012.

37.

Spruit MA, Gosselink R, Troosters T, Kasran A, Gayan-Ramirez G, Bogaerts P, Bouillon R, Decramer M: Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax. 2003, 58: 752-756. 10.1136/thorax.58.9.752.PubMedPubMedCentral

38.

Crul T, Testelmans D, Spruit MA, Troosters T, Gosselink R, Geeraerts I, Decramer M, Gayan-Ramirez G: Gene expression profiling in vastus lateralis muscle during an acute exacerbation of COPD. Cell Physiol Biochem. 2010, 25: 491-500. 10.1159/000303054.PubMed

39.

Kim HC, Mofarrahi M, Hussain SN: Skeletal muscle dysfunction in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008, 3: 637-658.PubMedPubMedCentral

40.

Vianna LG, Koulouris N, Lanigan C, Moxham J: Effect of acute hypercapnia on limb muscle contractility in humans. J Appl Physiol. 1990, 69: 1486-1493.PubMed

41.

Juan G, Calverley P, Talamo C, Schnader J, Roussos C: Effect of carbon dioxide on diaphragmatic function in human beings. N Engl J Med. 1984, 310: 874-879. 10.1056/NEJM198404053101402.PubMed

42.

Vermeeren M, Schols A, Wouters E: Effects of an acute exacerbation on nutritional and metabolic profile of patients with COPD. Euro Respir J. 1997, 10: 2264-2269. 10.1183/09031936.97.10102264.

43.

Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J, Carone M, Celli B, Engelen M, Fahy B, et al: American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med. 2006, 173: 1390-1413. 10.1164/rccm.200508-1211ST.PubMed

44.

Vestbo J, Prescott E, Almdal T, Dahl M, Nordestgaard BG, Andersen T, Sorensen TI, Lange P: Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med. 2006, 173: 79-83.PubMed

45.

Maurer J, Rebbapragada V, Borson S, Goldstein R, Kunik ME, Yohannes AM, Hanania NA: Anxiety and depression in copd: current understanding, unanswered questions, and research needs. CHEST Journal. 2008, 134: 43S-56S. 10.1378/chest.08-0342.

46.

Bhandari NJ, Jain T, Marolda C, ZuWallack RL: Comprehensive pulmonary rehabilitation results in clinically meaningful improvements in anxiety and depression in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil Prev. 2013, 33: 123-127. 10.1097/HCR.0b013e31828254d4.PubMed

47.

Lacasse Y, Goldstein R, Lasserson TJ, Martin S: Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006, 4: CD003793

48.

Puhan MA, Gimeno-Santos E, Scharplatz M, Troosters T, Walters EH, Steurer J: Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011, 10: CD005305

49.

Kon SS, Canavan JL, Man WD: Pulmonary rehabilitation and acute exacerbations of COPD. Expert Rev Respir Med. 2012, 6: 523-531. 10.1586/ers.12.47. quiz 531PubMed

50.

Seymour JM, Moore L, Jolley CJ, Ward K, Creasey J, Steier JS, Yung B, Man WD, Hart N, Polkey MI, et al: Outpatient pulmonary rehabilitation following acute exacerbations of COPD. Thorax. 2010, 65: 423-428. 10.1136/thx.2009.124164.PubMed

51.

Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M, Gosselink R: Physical activity and hospitalization for exacerbation of COPD. Chest. 2006, 129: 536-544. 10.1378/chest.129.3.536.PubMed

52.

Eaton T, Young P, Fergusson W, Moodie L, Zeng I, O’Kane F, Good N, Rhodes L, Poole P, Kolbe J: Does early pulmonary rehabilitation reduce acute health-care utilization in COPD patients admitted with an exacerbation? A randomized controlled study. Respirology. 2009, 14: 230-238. 10.1111/j.1440-1843.2008.01418.x.PubMed

53.

Ko FW, Dai DL, Ngai J, Tung A, Ng S, Lai K, Fong R, Lau H, Tam W, Hui DS: Effect of early pulmonary rehabilitation on health care utilization and health status in patients hospitalized with acute exacerbations of COPD. Respirology. 2011, 16: 617-624. 10.1111/j.1440-1843.2010.01921.x.PubMed

54.

Puhan MA, Spaar A, Frey M, Turk A, Brandli O, Ritscher D, Achermann E, Kaelin R, Karrer W: Early versus late pulmonary rehabilitation in chronic obstructive pulmonary disease patients with acute exacerbations: a randomized trial. Respiration. 2012, 83: 499-506. 10.1159/000329884.PubMed

55.

Maddocks M, Gao W, Higginson IJ, Wilcock A: Neuromuscular electrical stimulation for muscle weakness in adults with advanced disease. Cochrane Database Syst Rev. 2013, 1: CD009419

56.

Dyer F, Flude L, Bazari F, Jolley C, Englebretsen C, Lai D, Polkey MI, Hopkinson NS: Non-invasive ventilation (NIV) as an aid to rehabilitation in acute respiratory disease. BMC Pulm Med. 2011, 11: 58-10.1186/1471-2466-11-58.PubMedPubMedCentral

57.

Raskin J, Spiegler P, McCusker C, ZuWallack R, Bernstein M, Busby J, DiLauro P, Griffiths K, Haggerty M, Hovey L, et al: The effect of pulmonary rehabilitation on healthcare utilization in chronic obstructive pulmonary disease: the northeast pulmonary rehabilitation consortium. J Cardiopulm Rehabil. 2006, 26: 231-236. 10.1097/00008483-200607000-00006.PubMed

58.

Cecins N, Geelhoed E, Jenkins SC: Reduction in hospitalisation following pulmonary rehabilitation in patients with COPD. Aust Health Rev. 2008, 32: 415-422. 10.1071/AH080415.PubMed

59.

Hui KP, Hewitt AB: A simple pulmonary rehabilitation program improves health outcomes and reduces hospital utilization in patients with COPD. Chest. 2003, 124: 94-97. 10.1378/chest.124.1.94.PubMed

60.

Chakravorty I, Fasakin C, Paine T, Narasimhaiah D, Austin G: Outpatient-based pulmonary rehabilitation for COPD: a cost of illness study. ISRN Pulmonol. 2011, 2011: 6.

61.

Griffiths TL, Burr ML, Campbell IA, Lewis-Jenkins V, Mullins J, Shiels K, Turner-Lawlor PJ, Payne N, Newcombe RG, Ionescu AA, et al: Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial. Lancet. 2000, 355: 362-368. 10.1016/S0140-6736(99)07042-7.PubMed

62.

Guell R, Casan P, Belda J, Sangenis M, Morante F, Guyatt GH, Sanchis J: Long-term effects of outpatient rehabilitation of COPD: a randomized trial. Chest. 2000, 117: 976-983. 10.1378/chest.117.4.976.PubMed

63.

Engstrom CP, Persson LO, Larsson S, Sullivan M: Long-term effects of a pulmonary rehabilitation programme in outpatients with chronic obstructive pulmonary disease: a randomized controlled study. Scand J Rehabil Med. 1999, 31: 207-213. 10.1080/003655099444371.PubMed

64.

Ries AL, Kaplan RM, Limberg TM, Prewitt LM: Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med. 1995, 122: 823-832. 10.7326/0003-4819-122-11-199506010-00003.PubMed

65.

Plant PK, Owen JL, Elliott MW: Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial. Lancet. 2000, 355: 1931-1935. 10.1016/S0140-6736(00)02323-0.PubMed

66.

British Thoracic Society, Royal College of Physicians (London), Intensive Care Society: The Use of Non-Invasive Ventilation in the management of patients with chronic obstructive pulmonary disease admitted to hospital with acute type II respiratory failure (with particular reference to Bilevel positive pressure ventilation). 2008, London: British Thoracic Society, Royal College of Physicians (London), Intensive Care Society

67.

Kallet RH, Diaz JV: The physiologic effects of noninvasive ventilation. Respir Care. 2009, 54: 102-115.PubMed

68.

Nickol AH, Hart N, Hopkinson NS, Hamnegard CH, Moxham J, Simonds A, Polkey MI: Mechanisms of improvement of respiratory failure in patients with COPD treated with NIV. Int J Chron Obstruct Pulmon Dis. 2008, 3: 453-462.PubMedPubMedCentral

69.

Tuggey JM, Plant PK, Elliott MW: Domiciliary non-invasive ventilation for recurrent acidotic exacerbations of COPD: an economic analysis. Thorax. 2003, 58: 867-871. 10.1136/thorax.58.10.867.PubMedPubMedCentral

70.

Casanova C, Celli BR, Tost L, Soriano E, Abreu J, Velasco V, Santolaria F: Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with severe COPD. Chest. 2000, 118: 1582-1590. 10.1378/chest.118.6.1582.PubMed

71.

Clini E, Sturani C, Rossi A, Viaggi S, Corrado A, Donner CF, Ambrosino N: The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. Eur Respir J. 2002, 20: 529-538. 10.1183/09031936.02.02162001.PubMed

72.

McEvoy RD, Pierce RJ, Hillman D, Esterman A, Ellis EE, Catcheside PG, O’Donoghue FJ, Barnes DJ, Grunstein RR: Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial. Thorax. 2009, 64: 561-566. 10.1136/thx.2008.108274.PubMed

73.

Chu CM, Chan VL, Lin AW, Wong IW, Leung WS, Lai CK: Readmission rates and life threatening events in COPD survivors treated with non-invasive ventilation for acute hypercapnic respiratory failure. Thorax. 2004, 59: 1020-1025. 10.1136/thx.2004.024307.PubMedPubMedCentral

74.

Cheung AP, Chan VL, Liong JT, Lam JY, Leung WS, Lin A, Chu CM: A pilot trial of non-invasive home ventilation after acidotic respiratory failure in chronic obstructive pulmonary disease. Int J Tuberc Lung Dis. 2010, 14: 642-649.PubMed

75.

Funk GC, Breyer MK, Burghuber OC, Kink E, Kirchheiner K, Kohansal R, Schmidt I, Hartl S: Long-term non-invasive ventilation in COPD after acute-on-chronic respiratory failure. Respir Med. 2011, 105: 427-434. 10.1016/j.rmed.2010.09.005.PubMed

76.

Lloyd-Owen SJ, Donaldson GC, Ambrosino N, Escarabill J, Farre R, Fauroux B, Robert D, Schoenhofer B, Simonds AK, Wedzicha JA: Patterns of home mechanical ventilation use in Europe: results from the Eurovent survey. Eur Respir J. 2005, 25: 1025-1031. 10.1183/09031936.05.00066704.PubMed

77.

NAMDRC: Clinical indications for noninvasive positive pressure ventilation in chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation–a consensus conference report. Chest. 1999, 116: 521-534.

78.

Costello R, Deegan P, Fitzpatrick M, McNicholas WT: Reversible hypercapnia in chronic obstructive pulmonary disease: a distinct pattern of respiratory failure with a favorable prognosis. Am J Med. 1997, 102: 239-244. 10.1016/S0002-9343(97)00017-X.PubMed

79.

McNally E, Fitzpatrick M, Bourke S, Costello R, McNicholas WT: Reversible hypercapnia in acute exacerbations of chronic obstructive pulmonary disease (COPD). Eur Respir J. 1993, 6: 1353-1356.PubMed

80.

Murphy P, Gibson GJ, Polkey MI, Hart N: HOT HMV UK: prevalence of persistent significant hypercapnia following acute exacerbation of COPD (AECOPD) requiring non-invasive ventilation (NIV) [Abstract]. Thorax. 2010, 65: A33.

81.

http://www.clinicaltrials.gov NCT00990132

82.

http://www.trialregister.nl NTR1100

83.

Miro AM, Shivaram U, Hertig I: COntinuous positive airway pressure in copd patients in acute hypercapnic respiratory failure. CHEST Journal. 1993, 103: 266-268. 10.1378/chest.103.1.266.

84.

Goldberg P, Reissmann H, Maltais F, Ranieri M, Gottfried SB: Efficacy of noninvasive CPAP in COPD with acute respiratory failure. Eur Respir J. 1995, 8: 1894-1900. 10.1183/09031936.95.08111894.PubMed

85.

Anthonisen NR, Connett JE, Enright PL, Manfreda J: Lung health study research G: hospitalizations and mortality in the lung health study. Am J Respir Crit Care Med. 2002, 166: 333-339. 10.1164/rccm.2110093.PubMed

86.

Kessler R, Faller M, Fourgaut G, Mennecier B, Weitzenblum E: Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999, 159: 158-164. 10.1164/ajrccm.159.1.9803117.PubMed

87.

Garcia-Aymerich J, Monso E, Marrades RM, Escarrabill J, Felez MA, Sunyer J, Anto JM: Risk factors for hospitalization for a chronic obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med. 2001, 164: 1002-1007. 10.1164/ajrccm.164.6.2006012.PubMed

88.

Godtfredsen NS, Vestbo J, Osler M, Prescott E: Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study. Thorax. 2002, 57: 967-972. 10.1136/thorax.57.11.967.PubMedPubMedCentral

89.

Au DH, Bryson CL, Chien JW, Sun H, Udris EM, Evans LE, Bradley KA: The effects of smoking cessation on the risk of chronic obstructive pulmonary disease exacerbations. J Gen Intern Med. 2009, 24: 457-463. 10.1007/s11606-009-0907-y.PubMedPubMedCentral

90.

Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet. 1981, 1: 681-686.

91.

Is 12-hour oxygen as effective as 24-hour oxygen in advanced chronic obstructive pulmonary disease with hypoxemia? (The Nocturnal Oxygen Therapy Trial–NOTT). Chest. 1980, 78: 419-420.

92.

Ringbaek TJ, Viskum K, Lange P: Does long-term oxygen therapy reduce hospitalisation in hypoxaemic chronic obstructive pulmonary disease?. Eur Respir J. 2002, 20: 38-42. 10.1183/09031936.02.00284202.PubMed

93.

Hurst JR, Donaldson GC, Perera WR, Wilkinson TM, Bilello JA, Hagan GW, Vessey RS, Wedzicha JA: Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006, 174: 867-874. 10.1164/rccm.200604-506OC.PubMed

94.

Rosenberg SR, Kalhan R: Biomarkers in chronic obstructive pulmonary disease. Translational Res. 2012, 159: 228-237. 10.1016/j.trsl.2012.01.019.

95.

Stevenson NJ, Walker PP, Costello RW, Calverley PMA: Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005, 172: 1510-1516. 10.1164/rccm.200504-595OC.PubMed

96.

Murphy PB, Kumar A, Reilly C, Jolley C, Walterspacher S, Fedele F, Hopkinson NS, Man WD, Polkey MI, Moxham J, et al: Neural respiratory drive as a physiological biomarker to monitor change during acute exacerbations of COPD. Thorax. 2011, 66: 602-608. 10.1136/thx.2010.151332.PubMed

97.

Cotton MM, Bucknall CE, Dagg KD, Johnson MK, MacGregor G, Stewart C, Stevenson RD: Early discharge for patients with exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Thorax. 2000, 55: 902-906. 10.1136/thorax.55.11.902.PubMedPubMedCentral

98.

Skwarska E, Cohen G, Skwarski KM, Lamb C, Bushell D, Parker S, MacNee W: Randomized controlled trial of supported discharge in patients with exacerbations of chronic obstructive pulmonary disease. Thorax. 2000, 55: 907-912. 10.1136/thorax.55.11.907.PubMedPubMedCentral

99.

Jeppesen E, Brurberg KG, Vist GE, Wedzicha JA, Wright JJ, Greenstone M, Walters JA: Hospital at home for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012, 5: CD003573

100.

McLean S, Nurmatov U, Liu JL, Pagliari C, Car J, Sheikh A: Telehealthcare for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011, 7: CD007718

101.

McKinstry B, Pinnock H, Sheikh A: Telemedicine for management of patients with COPD?. Lancet. 2009, 374: 672-673. 10.1016/S0140-6736(09)61542-7.PubMed

102.

Bolton CE, Waters CS, Peirce S, Elwyn G: Insufficient evidence of benefit: a systematic review of home telemonitoring for COPD. J Eval Clin Prac. 2011, 17: 1216-1222. 10.1111/j.1365-2753.2010.01536.x.

103.

Polisena J, Tran K, Cimon K, Hutton B, McGill S, Palmer K, Scott RE: Home telehealth for chronic obstructive pulmonary disease: a systematic review and meta-analysis. J Telemed Telecare. 2010, 16: 120-127. 10.1258/jtt.2009.090812.PubMed

104.

Steventon A, Bardsley M, Billings J, Dixon J, Doll H, Hirani S, Cartwright M, Rixon L, Knapp M, Henderson C, et al: Effect of telehealth on use of secondary care and mortality: findings from the whole system demonstrator cluster randomised trial. BMJ. 2012, 344: e3874-10.1136/bmj.e3874.PubMedPubMedCentral

105.

Cartwright M, Hirani SP, Rixon L, Beynon M, Doll H, Bower P, Bardsley M, Steventon A, Knapp M, Henderson C, et al: Effect of telehealth on quality of life and psychological outcomes over 12 months (Whole Systems Demonstrator Telehealth Questionnaire Study): nested study of patient reported outcomes in a pragmatic, cluster randomised controlled trial. BMJ. 2013, 346: f653-10.1136/bmj.f653.PubMedPubMedCentral

106.

Henderson C, Knapp M, Fernandez JL, Beecham J, Hirani SP, Cartwright M, Rixon L, Beynon M, Rogers A, Bower P, et al: Cost effectiveness of telehealth for patients with long term conditions (Whole Systems Demonstrator Telehealth Questionnaire Study): nested economic evaluation in a pragmatic, cluster randomised controlled trial. BMJ. 2013, 346: f1035-10.1136/bmj.f1035.PubMed

107.

Pinnock H, Hanley J, Lewis S, MacNee W, Pagliari C, van der Pol M, Sheikh A, McKinstry B: The impact of a telemetric chronic obstructive pulmonary disease monitoring service: randomised controlled trial with economic evaluation and nested qualitative study. Prim Care Respir J. 2009, 18: 233-235. 10.4104/pcrj.2009.00040.PubMed

108.

Advancing Care Coordination and Telehealth Deployment. http://www.act-program.eu/.

Title: Admission prevention in COPD: non-pharmacological management
Authors: Eui-Sik Suh
Swapna Mandal
Nicholas Hart
Publication date: 01-12-2013
Publisher: BioMed Central
Published in: BMC Medicine / Issue 1/2013
Electronic ISSN: 1741-7015
DOI: https://doi.org/10.1186/1741-7015-11-247

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Admission prevention in COPD: non-pharmacological management

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

Implications of the licensure of a partially efficacious malaria vaccine on evaluating second-generation vaccines

Pharmacological treatments in ARDS; a state-of-the-art update

Patient advocacy and DSM-5

Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cells

16/6-idiotype expressing antibodies induce brain inflammation and cognitive impairment in mice: the mosaic of central nervous system involvement in lupus

Transmission potential of influenza A/H7N9, February to May 2013, China